Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Helios Double Nickase Plasmid (h2): sc-402984-NIC-2
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Helios Double Nickase Plasmid (h2) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Helios Double Nickase Plasmid (h2) and Helios Double Nickase Plasmid (h22) encode distinct paired gRNA designs targeting IKZF2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Helios Antibody (E-7): sc-390357
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Helios Double Nickase Plasmid (h2) | sc-402984-NIC-2 | 20 µg | $410.00 |
Human IKZF2 encodes Helios, a zinc finger transcription factor of the Ikaros family that binds DNA to regulate gene expression programs governing lymphocyte lineage commitment, thymocyte maturation, and T cell functional specialization. Helios participates in chromatin-associated transcriptional networks that shape TCR-driven activation, cytokine signaling responses, and epigenetic control of immune tolerance, with prominent roles in regulatory T cell stability and immune homeostasis. Altered IKZF2/Helios expression or activity has been associated with immune dysregulation and hematologic malignancy contexts, including changes in T cell differentiation states and leukemic transcriptional profiles. IKZF2 research tools support mechanistic studies of transcription factor occupancy, gene regulatory circuitry, and cell-state transitions in human immunology models using CRISPR-based perturbation, reporter assays, and multi-omics profiling.
Helios Double Nickase Plasmid (h2) consists of a matched pair of plasmids engineered for high-specificity editing of the IKZF2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within IKZF2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt IKZF2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of IKZF2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.